Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis.

Philippe Manceau 1, * Clotilde Latarche 2 Sophie Pittion 1 Gilles Edan 3, 4, 5 Jérôme De Sèze 6 Catherine Massart 4, 7 Marc Debouverie 8, 1, 2
* Auteur correspondant
3 VisAGeS - Vision, Action et Gestion d'informations en Santé
INSERM - Institut National de la Santé et de la Recherche Médicale : U746, Inria Rennes – Bretagne Atlantique , IRISA-D5 - SIGNAUX ET IMAGES NUMÉRIQUES, ROBOTIQUE
8 Ecole de Santé Publique [Nancy]
Faculté de Médecine [Nancy]
Abstract : BackgroundThe clinical impact of neutralizing antibodies against interferon-beta (NAb) is controversial. Their presence can lead to a decrease in interferon-beta (IFNß) efficacy. Fatigue reported in patients with multiple sclerosis (MS) may be associated with an unfavorable clinical course. We conducted a prospective multicentre study to assess the association between response to IFNß, NAb and fatigue.MethodsPatients with relapsing-remitting MS on IFNß treatment were included. During the second year of treatment, the patients were analyzed for NAb status and non-response criteria to IFNß (number of relapses ¿1 during the follow-up period, increase in the Expanded Disability Status Scale ¿0.5). The score on the Modified Fatigue Impact Scale (MFIS pathological if score ¿35) was noted for each patient.ResultsOf the 176 patients included: 22.3% were NAb positive, 54.5% presented non-response criteria to IFNß, and 57.4% had a pathological MFIS score. Fatigue was increased in NAb¿+¿patients (p¿=¿0.0014) and they were more likely to present non-response criteria to IFNß (p¿=¿0.041) than NAb- patients. Multivariate logistic regression analysis showed that the presence of NAb was related to fatigue (p¿=¿0.0032) and denoted disease activity in these patients (p¿=¿0.026).ConclusionsThis study demonstrates the impact of NAb on the non-clinical response to IFNß. Fatigue assessment is an indicator of IFNß responsiveness and a predictive biomarker of deterioration on patient¿s neurological status.
Type de document :
Article dans une revue
BMC Neurology, BioMed Central, 2014, 14 (1), pp.215. 〈10.1186/s12883-014-0215-y〉
Liste complète des métadonnées

Littérature citée [40 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-01103114
Contributeur : Christine Dupuis <>
Soumis le : mardi 20 janvier 2015 - 11:02:26
Dernière modification le : mercredi 16 mai 2018 - 11:23:11
Document(s) archivé(s) le : vendredi 11 septembre 2015 - 07:42:30

Fichier

Manceau et al. BMC Neurology 2...
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

Citation

Philippe Manceau, Clotilde Latarche, Sophie Pittion, Gilles Edan, Jérôme De Sèze, et al.. Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis.. BMC Neurology, BioMed Central, 2014, 14 (1), pp.215. 〈10.1186/s12883-014-0215-y〉. 〈inserm-01103114v2〉

Partager

Métriques

Consultations de la notice

335

Téléchargements de fichiers

163